Finland Sees Progress On Biosimilar Substitution Plans
Updated Proposals Reflect Industry Criticism; Parliamentary Approval Expected In Weeks
Updated plans to implement pharmacy-level biosimilar substitution in Finland have been published by a parliamentary health committee ahead of expected formal approval within weeks, reflecting certain industry criticisms that have now been taken on board.
You may also be interested in...
EMA-HMA Biosimilar Interchangeability Statement Offers ‘Unity And Clarity’ For Europe
The recent statement by the EMA and HMA affirming the interchangeability of biologics and biosimilars has given a boost to Europe’s biosimilars industry ahead of key legislative reforms, heard delegates to Medicines for Europe’s 18th Biosimilar Medicines Conference in Brussels.
Stakeholders Surprised As French Biosimilar Substitution Changes Tack
The latest step towards biosimilar substitution taken by the French authorities has left stakeholders baffled by an unexplained shift in approach, including a change to the specific biologic molecules that have been selected as eligible for substitution.
Trio Of Hikma Launches Includes New Icosapent Strength
Hikma has launched three new generics in quick succession, including a new strength of its icosapent ethyl capsules that rival Vascepa, as well as unique presentations of its cefazolin and labetalol injectables.